Therapeutic Classification: sedative/hypnotics
Pharmacologic Classification: orexin receptor antagonists
Absorption: 82% absorbed following oral administration; a high-fat meal will delay absorption and sleep onset. ↑ absorption in obese females.
Distribution: Well distributed to tissues.
Protein Binding: >99%.
Half-Life: 12 hr (↑ in hepatic impairment).
(sleep)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | 30 min (delayed by food) | unknown | 7 hr‡ |
‡Excess sedation may persist for several days after discontinuation.
Contraindicated in:
Use Cautiously in:
Adverse reactions, especially related to CNS depression are dose-related, especially at the 20-mg dose
Neuro: drowsiness, cataplexy, complex sleep behaviors (including sleep driving, sleep walking, or engaging in other activities while sleeping), daytime drowsiness, hallucinations (during sleep), sleep paralysis, worsening of depression/suicidal ideation
Drug-drug: